About
Bispecific antibody and iPSC-derived, TALEN gene-edited NK-cell platforms
Areas of Focus
Categories
Biologics & BiopharmaceuticalAI FocusedAntibodyBoston & New England
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
448
By Phase
PHASE1/PHASE2: 2
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06971523Lead Sponsor
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
PHASE1/PHASE2Recruiting
224 participants
Started: Dec 25, 2024 · Completed: Jun 30, 2029
NCT06224387Lead Sponsor
CTS2190 Phase I /II Clinical Study in Patients
PHASE1/PHASE2Recruiting
224 participants
Started: Jun 26, 2023 · Completed: Oct 31, 2025
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...